Relmada Therapeutics, Inc. (RLMD): Price and Financial Metrics


Relmada Therapeutics, Inc. (RLMD): $4.60

0.00 (0.00%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add RLMD to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

RLMD Stock Price Chart Interactive Chart >

Price chart for RLMD

RLMD Price/Volume Stats

Current price $4.60 52-week high $38.68
Prev. close $4.60 52-week low $4.34
Day low $4.34 Volume 806,100
Day high $4.66 Avg. volume 501,952
50-day MA $13.91 Dividend yield N/A
200-day MA $21.42 Market Cap 138.46M

Relmada Therapeutics, Inc. (RLMD) Company Bio


Relmada Therapeutics, Inc. is a clinical stage, public specialty pharmaceutical company who develops a variety of established drug products. The Company also researches and procures chemical entities with a focus on the treatment of pain.


RLMD Latest News Stream


Event/Time News Detail
Loading, please wait...

RLMD Latest Social Stream


Loading social stream, please wait...

View Full RLMD Social Stream

Latest RLMD News From Around the Web

Below are the latest news stories about RELMADA THERAPEUTICS INC that investors may wish to consider to help them evaluate RLMD as an investment opportunity.

Relmada Therapeutics Provides Corporate Update and Reports Third Quarter 2022 Financial Results

Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today provided a corporate update and announced preliminary and unaudited financial results for the three and nine months ended September 30, 2022. The Company will host a conference call today, Thursday, November 10, at 4:30 PM Eastern Time/1:30 PM Pacific Time.

Yahoo | November 10, 2022

Relmada Therapeutics to Report Third Quarter 2022 Financial Results and Host Conference Call and Webcast on November 10, 2022

Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that it will report its financial results for the third quarter and nine months ended September 30, 2022 after the market close on Thursday, November 10, 2022. The company will host a corporate update conference call and live audio webcast at 4:30 PM Eastern Time on Thursday, November 10, 2022.

Yahoo | November 8, 2022

We Think Relmada Therapeutics (NASDAQ:RLMD) Needs To Drive Business Growth Carefully

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...

Yahoo | November 3, 2022

Biotech Stock Roundup: NERV, RLMD Down on Updates, MRNA, NVAX's News & More

Regulatory and pipeline updates from NERV and RLMD are the key highlights from the biotech sector during the past week.

Yahoo | October 20, 2022

Relmada (RLMD) Lead Candidate Fails Late-Stage Depression Study

Relmada's (RLMD) phase III study, evaluating REL-1017 in major depressive disorder, fails to achieve statistical significance. Shares plunge 80% following the news.

Yahoo | October 14, 2022

Read More 'RLMD' Stories Here

RLMD Price Returns

1-mo -27.67%
3-mo N/A
6-mo -76.61%
1-year -72.83%
3-year -89.05%
5-year 59.72%
YTD -79.58%
2021 -29.75%
2020 -17.77%
2019 747.83%
2018 53.33%
2017 -31.19%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.8595 seconds.